MiR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression

Cancer Letters

Volumn 304, Issue 1, 2011, Pages 52-59

  Li, Jian ^a,b   Chen, Yuxiang ^a   Zhao, Jingfeng ^b   Kong, Fangren ^a   Zhang, Yangde ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; Colon cancer; MiR 203; MiRNA; Paclitaxel

Indexed keywords

CELL PROTEIN; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MICRORNA; MICRORNA 203; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B BETA; PROTEIN MTDH; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; RNA DEGRADATION; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952241662     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.003     Document Type: Article

References (42)

1. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20:515-524.
2. Bagga S., Pasquinelli A.E. Identification and analysis of microRNAs. Genet. Eng. (NY) 2006, 27:1-20.
3. Bar N., Dikstein R. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 2010, 5:e10859.
4. Sonkoly E., Wei T., Pavez Loriè E., Suzuki H., Kato M., Törmä H., Ståhle M., Pivarcsi A. Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J. Invest. Dermatol. 2010, 130:124-134.
5. McKenna D.J., McDade S.S., Patel D., McCance D.J. MicroRNA 203 expression in keratinocytes is dependent on regulation of p53 levels by E6. J. Virol. 2010, 84:10644-10652.
6. Xiong J., Du Q., Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 2010, 29:4980-4988.
7. Yi R., Poy M.N., Stoffel M., Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008, 452:225-229.
8. Bostjancic E., Glavac D. Importance of microRNAs in skin morphogenesis and diseases. Acta. Dermatovenerol. Alp. Panonica. Adriat. 2008, 17:95-102.
9. Ikenaga N., Ohuchida K., Mizumoto K., Yu J., Kayashima T., Sakai H., Fujita H., Nakata K., Tanaka M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann. Surg. Oncol. 2010, 17:3120-3128.
10. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
11. Yantiss R.K., Goodarzi M., Zhou X.K., Rennert H., Pirog E.C., Banner B.F., Chen Y.T. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am. J. Surg. Pathol. 2009, 33:572-582.
12. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
13. Y. Chiang, Y. Song, Z. Wang, Y. Chen, Z. Yue, H. Xu, C. Xing, Z. Liu, Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers, J. Gastrointest. Surg. (2010) (Epub. ahead of print).
14. Bandrés E., Cubedo E., Agirre X., Malumbres R., Zárate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzó M., García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5:29.
15. Cancer, National Cancer Institute, 2009. http://www.cancer.gov/cancertopics.
16. Xu A.G., Yu Z.J., Jiang B., Wang X.Y., Zhong X.H., Liu J.H., Lou Q.Y., Gan A.H. Colorectal cancer in Guangdong Province of China: A demographic and anatomic survey. World J. Gastroenterol. 2010, 16:960-965.
17. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology 2009, 23:162-167.
18. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
19. Dai Z., Huang Y., Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr. Top Med. Chem. 2004, 4:1347-1356.
20. McDonald G.T., Sullivan R., Paré G.C., Graham C.H. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp. Cell Res. 2010, 316:3197-3206.
21. Huang W.C., Hung M.C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc. 2009, 108:180-194.
22. Li Z., Thiele C.J. Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Exp. Opin. Ther. Targets 2007, 11:1611-1621.
23. Zhang X., Mi J., Wetsel W.C., Davidson C., Xiong X., Chen Q., Ellinwood E.H., Lee T.H. PI3Kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. Biochem. Biophys. Res. Commun. 2006, 340:1144-1150.
24. Sasabe E., Tatemoto Y., Li D., Yamamoto T., Osaki Y. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci. 2005, 96:394-402.
25. Emdad L., Sarkar D., Su Z.Z., Randolph A., Boukerche H., Valerie K., Fisher P.B. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res. 2006, 66:1509-1516.
26. Lee S.G., Su Z.Z., Emdad L., Sarkar D., Fisher P.B. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc. Natl. Acad. Sci. USA 2006, 103:17390-17395.
27. Pham A.N., Blower P.E., Alvarado O., Ravula R., Gout P.W., Huang Y. Pharmacogenomic approach reveals a role for the x(c)-cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J. Pharmacol. Exp. Ther. 2010, 332:949-958.
28. Hiro J., Inoue Y., Toiyama Y., Yoshiyama S., Tanaka K., Mohri Y., Miki C., Kusunoki M. Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer. Oncol. Rep. 2010, 24:1029-1034.
29. Djeu J.Y., Wei S. Clusterin and chemoresistance. Adv. Cancer Res. 2009, 105:77-92.
30. Argov M., Bod T., Batra S., Margalit R. Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization. Eur. J. Pharm. Sci. 2010, 41:53-59.
31. Zhang X., Li Y., Huang Q., Wang H., Yan B., Dewhirst M.W., Li C.Y. Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. Clin. Cancer Res. 2003, 9:1155-1160.
32. Mi J., Zhang X., Rabbani Z.N., Liu Y., Su Z., Vujaskovic Z., Kontos C.D., Sullenger B.A., Clary B.M. H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Res. 2006, 34:3577-3584.
33. Hu G., Wei Y., Kang Y. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin. Cancer Res. 2009, 15:5615-5620.
34. Djeu J.Y., Wei S. Clusterin and chemoresistance. Adv. Cancer Res. 2009, 105:77-92.
35. McEwan D.G., Brunton V.G., Baillie G.S., Leslie N.R., Houslay M.D., Frame M.C. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 2007, 67:5248-5257.
36. Rinne T., Brunner H.G., van Bokhoven H. p63-associated disorders. Cell Cycle 2007, 6:262-268.
37. Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G.H., et al. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol. Syst. Biol. 2008, 4:229.
38. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
39. Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 2005, 23:7518-7528.
40. Blanco-Aparicio C., Renner Q., Leal J.F., Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28:1379-1386.
41. Hu G., Chong R.A., Yang Q., Wei Y., Blanco M.A., Li F., Reiss M., Au J.L., Haffty B.G., Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15:9-20.
42. Lee S.G., Su Z.Z., Emdad L., Sarkar D., Franke T.F., Fisher P.B. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008, 27:1114-1121.